Novo Nordisk Reports Big Results for New Weight Loss Drug
Novo Nordisk says its new drug CagriSema helped women lose a quarter of their body weight in late trials.
The race to treat weight gain heats up. Millions of people seek better health options every year. Drug makers work to build stronger tools.
Novo Nordisk has a new medicine named CagriSema. The company tested this shot in a late-stage trial. Women in the study lost 25 percent of their body weight. That beats the track record of Wegovy, their current hit drug.
CagriSema combines two hormones into one weekly injection. This design calms hunger for longer periods. Patients stayed on track through the tests. Novo expects to submit data to regulators soon.
This progress gives patients better choices for their health. It also keeps Novo Nordisk ahead in a booming market. New treatments create more paths to healthy living.
Source: CNBC
More from Biotech
